VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX
Delisted
VIRX was delisted on the 3rd of February, 2025.
40 hedge funds and large institutions have $6.42M invested in Viracta Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 13 reducing their positions, and 14 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
81% less capital invested
Capital invested by funds: $33M → $6.42M (-$26.6M)
Holders
40
Holding in Top 10
1
Calls
$82K
Puts
$5K
Top Buyers
| 1 | +$251K | |
| 2 | +$50.6K | |
| 3 | +$27.9K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$11K |
| 5 |
Morgan Stanley
New York
|
+$10.9K |
Top Sellers
| 1 | -$4.25M | |
| 2 | -$747K | |
| 3 | -$365K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$286K |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$283K |